Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06377631
Other study ID # FATHIS+
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date May 2025

Study information

Verified date April 2024
Source Fundació Eurecat
Contact Xavier Escoté, PhD
Phone +34 977 300 431
Email xavier.escote@eurecat.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to evaluate the effect of daily intake of a specific combination of different natural histidine-related amino acids in combination with dietary recommendations, in the reduction of visceral fat, as well as their associated comorbidities, in postmenopausal women with abdominal obesity.


Description:

In postmenopausal women, the risk of non-alcoholic fatty liver disease (NAFLD) increases due to hormonal changes and metabolic shifts. Menopause leads to a decline in estrogen levels, affecting lipid metabolism and promoting abdominal and visceral fat accumulation. This visceral adiposity poses a significant risk factor for insulin resistance, type 2 diabetes, dyslipidemia, cardiovascular diseases, and NAFLD. While the prevalence of NAFLD is initially higher in men, it becomes comparable or even higher in postmenopausal women due to these metabolic changes. Studies suggest that estrogen deficiency post-menopause contributes to the development of NAFLD in women. Lower serum estrogen levels are associated with a higher likelihood of NAFLD development, indicating the potential role of hormone replacement therapy (HRT) in mitigating NAFLD risk in postmenopausal women. However, the use of HRT must be carefully evaluated due to potential adverse effects on cardiovascular health. Thus, novel, effective and safety therapeutic strategies for managing metabolic disorders in postmenopausal women are highly desirable. The main objective of this study is to evaluate the effect of daily intake of a specific combination of different natural histidine-related amino acids in combination with dietary recommendations, in the reduction of visceral fat in postmenopausal women with abdominal obesity. The secondary objectives of this study are to evaluate the effect of daily intake of the multi-ingredient aforementioned in liver function markers, anthropometric parameters, blood pressure and heart rate, markers of lipid metabolism, markers of glucidic metabolism, inflammatory markers, histidine serum levels, sexual hormones, the temperature of supraclavicular brown adipose tissue, changes in the intestinal microbiota, changes in the expression of lipid metabolism-related genes and symptoms associated with postmenopause. A randomized, parallel, placebo-controlled, single-center, triple-blind clinical trial with a 1:1:1 ratio between interventions with 50 participants will be conducted. During the study there will be 4 visits: a preselection visit (V0; day -7) and 3 study visits during the consumption of the treatments, which will take place on the first day of the study (V1; day 1 +/- 3 days; week 1), at 6 weeks of treatment (V2; day 43 +/- 3 day; week 6) and at 12 weeks of treatment (V3; day 85 +/- 3 days; week 12).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date May 2025
Est. primary completion date May 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria: - Postmenopausal women aged 50 to 65 years. - BMI =27.5 kg/m^2 and =32.5 kg/m^2. - Waist circumference =88 cm. - No hormone replacement therapy. - Read, write and speak Catalan or Spanish. - Sign the informed consent. Exclusion Criteria: - Present values of body mass index < 27.5 kg/m^2 or > 32.5 kg/m^2 - Present values of waist circumference > 115 cm. - Present diabetes. - Present dyslipidemia. - Present anemia. - Taking supplements, multivitamin supplements or phytotherapeutic products that interfere with the treatment under study. - Consume 2 or more Standard Beverage Units (SBU) daily or 17 SBU weekly. - Be a smoker. - Present any diagnosed liver disease other than NAFLD. - Have lost more than 3 kg of weight in the last 3 months. - Present food intolerances and/or allergies related to the study products, such as hypersensitivity to maltodextrin or N-Acetylcysteine. - Presenting any chronic or autoimmune disease in clinical manifestation such as hepatitis, hyper or hypothyroidism or metabolic diseases. - Follow a pharmacological treatment with immunosuppressants, cytotoxic agents, corticosteroids or other drugs that could cause hepatic steatosis or alter the measurements in the liver. - Being participating or having participated in a clinical trial or nutritional intervention study in the last 30 days before inclusion in the study. - Follow a hypocaloric diet and/or pharmacological treatment for weight loss. - Suffering from eating behavior disorders or psychiatric disorders. - Being unable to follow study guidelines.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Placebo
The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.

Locations

Country Name City State
Spain Anna Crescenti Reus Catalonia. Spain

Sponsors (4)

Lead Sponsor Collaborator
Fundació Eurecat Centre de Diagnosi per la Imatge, Instituto de Investigación Biomédica de Girona (IDIBGI), Laboratorio de Referencia de Cataluña

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Visceral Adiposity Visceral fat content measured using a dual energy x-ray absorptiometry (DXA) scanner Change from Baseline Visceral Adiposity at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Height (cm) Height measured with standardized method At baseline
Secondary Age The age of the volunteers will be recorded in the case report form. At day -7 (pre-selection visit)
Secondary Ethnicity The ethnicity of the volunteers will be recorded in the case report form. At day -7 (pre-selection visit)
Secondary Change in Body Weight (kg) Weight measured with standardized method Change from Baseline Weight at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Body Mass Index (BMI) (Kg/m^2) Weight and height will be combined to report BMI in kg/m^2 Change from Baseline Body Mass Index at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Neck circumference (cm) Neck circumference using a measuring tape Change from Baseline Neck circumference at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Arm circumference (cm) Arm circumference using a measuring tape Change from Baseline Arm circumference at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Waist circumference (cm) Waist circumference using a measuring tape Change from Baseline Waist circumference at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Hip circumference (cm) Hip circumference using a measuring tape Change from Baseline hip circumference at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Conicity Index Weight, height and waist circumference will be combined to report Conicity index. Change from Baseline Conicity Index at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Waist-to-Hip ratio Waist and Hip circumference will be combined to report Waist-to-Hip ratio Change from Baseline Waist-to-Hip ratio at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Lipid Accumulation Product (LAP) Waist circumference and fasting plasma Triglycerides will be combined to report Lipid Accumulation Product Change from Baseline Lipid Accumulation Product ratio at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Systolic Blood Pressure (mm Hg) Systolic blood pressure will be measured using an automatic sphygmomanometer Change from Baseline Systolic Blood Pressure at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Diastolic Blood Pressure (mm Hg) Diastolic blood pressure will be measured using an automatic sphygmomanometer Change from Baseline Systolic Blood Pressure at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in heart rate (bpm) Heart rate will be measured using an automatic sphygmomanometer Change from Baseline Heart rate at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum glucose levels (mg/dL) Serum glucose levels will be determined by standardized spectrophotometry methods Change from Baseline serum glucose levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum total cholesterol (mg/dL) Total cholesterol will be determined by standardized spectrophotometry methods Change from Baseline serum total cholesterol at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum high-density lipoprotein cholesterol (HDL-C,mg/dL) High-density lipoprotein cholesterol will be determined by standardized spectrophotometry methods Change from Baseline serum high-density lipoprotein cholesterol at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum low-density lipoprotein cholesterol (LDL-C, mg/dL) Low-density lipoprotein cholesterol will be calculated using the Friedewald formula Change from Baseline serum low-density lipoprotein cholesterol at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum triglycerides (TG, mg/dL) Triglycerides will be determined by standardized spectrophotometry methods Change from Baseline serum triglycerides at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum alanine aminotransferase (ALT, U/L) Alanine aminotransferase will be determined by standardized spectrophotometry methods Change from Baseline serum alanine aminotransferase at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum aspartate aminotransferase (AST, U/L) Aspartate aminotransferase will be determined by standardized spectrophotometry methods Change from Baseline serum aspartate aminotransferase at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum gamma glutamyl transferase (GGT, U/L) Gamma glutamyl transferase will be determined by standardized spectrophotometry methods Change from Baseline serum gamma glutamyl transferase at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum insulin levels (mU/L) Insulin levels will be measured by standardized chemiluminescence methods. Change from Baseline serum insulin levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum leptin levels (pg/mL) Leptin levels will be measured by standardized chemiluminescence methods Change from Baseline serum leptin levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum adiponectin levels (ng/mL) Adiponectin levels will be measured by standardized chemiluminescence methods Change from Baseline serum adiponectin levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Adiponectin/Leptin ratio (numerical ratio) Adiponectin and leptin will be combined to report adiponectin/leptin ratio Change from Baseline Adiponectin/Leptin ratio at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum Monocyte chemoattractant protein-1 (MCP-1) levels (pg/mL) MCP-1 levels will be measured by standardized chemiluminescence methods Change from Baseline serum MCP-1 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in plasma tumor necrosis factor alpha (TNF-alpha) levels (pg/mL) TNF-alpha levels will be measured by standardized chemiluminescence methods Change from Baseline plasma TNF-alpha levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in plasma Interleukin 6 (IL-6) levels (pg/mL) IL-6 levels will be measured by standardized chemiluminescence methods Change from Baseline plasma IL-6 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in plasma Interleukin 10 (IL-10) levels (pg/mL) IL-10 levels will be measured by standardized chemiluminescence methods Change from Baseline plasma IL-10 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in plasma Intercellular Adhesion Molecule 1 (ICAM-1) levels (ng/mL) ICAM-1 levels will be measured by standardized chemiluminescence methods Change from Baseline plasma ICAM-1 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in plasma Cluster of Differentiation 14 (CD14) levels (pg/mL) CD14 levels will be measured by standardized chemiluminescence methods Change from Baseline plasma CD14 levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in plasma oxidized low density lipoproteins (LDLox) levels (mU/L) LDLox levels will be measured by standardized chemiluminescence methods Change from Baseline plasma LDLox levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in serum C-Reactive protein levels (mg/L) C-Reactive protein levels will be determined by standardized spectrophotometry methods Change from Baseline serum C-Reactive protein levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Histidine levels in blood (umol/L) Serum histidine levels will be determined by Liquid Chromatography coupled to tandem Mass Spectrometry Change from Baseline Histidine levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Acylcarnitine levels in blood (umol/L) Serum Acylcarnitine levels will be determined by Liquid Chromatography coupled to tandem Mass Spectrometry Change from Baseline Acylcarnitine levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in 17-beta-estradiol (E2) levels in blood (pg/mL) Serum 17-beta-estradiol (E2) levels will be determined by standardized chemiluminescence methods Change from Baseline 17-beta-estradiol (E2) levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Follicle-stimulating hormone (FSH) levels in blood (mU/mL) Follicle-stimulating hormone (FSH) levels will be determined by standardized chemiluminescence methods Change from Baseline FSH levels at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Homeostatic Model Assessment from Insulin Resistance Index (HOMA-IR) HOMA-IR will be calculated using serum glucose and insulin levels. Change from Baseline HOMA-IR at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Fatty Liver Index (FLI) FLI will be calculated using BMI, waist circumference, serum triglycerides and gamma glutamyl transferase levels Change from Baseline FLI at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Triglyceride glucose index (TyG) TyG will be calculated using serum glucose and triglycerides levels Change from Baseline TyG at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Plasma atherogenic index Plasma atherogenic index will be calculated as the logarithm of the TG to HDL-c ratio Change from Baseline Plasma atherogenic index at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in lipidomic profile Lipidomic analyses will be done by Liquid Chromatography coupled to tandem Mass Spectrometry Change from Baseline Lipidomic profile at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in intestinal microbiota composition Metagenomic analysis in fecal samples. The bacteria DNA will be extracted and massive sequenced by the Ion Torrent platform. Change from Baseline intestinal microbiota composition at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in the expression of lipid-metabolism genes in PBMC Peripheral blood mononuclear cell (PBMC) will be isolated to obtain the RNA for gene expression analyses by Quantitative reverse transcription PCR (RT-qPCR) Change from Baseline gene expression at 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Dietary habits Nutritional habits will be determined based on the results obtained from the 3-day dietary record Change from Baseline Dietary habits at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in Physical activity Physical activity will be evaluated through the International Physical Activity Questionnaire (IPAQ)-short for physical activity questionnaire. Scores will be reported in categories: LOW activity levels, MODERATE activity levels or HIGH activity levels with the latter indicating better outcomes. Change from Baseline Physical activity at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Concomitant medication Concomitant medication consumed during the study will be recorded in the case report form. At day -7 (pre-selection visit), day 1 (visit V1), day 43 (visit 2) and day 85 (visit 3)
Secondary Consumption of dietary supplements Dietary supplements consumed during the study will be recorded in the case report form. At day -7 (pre-selection visit), day 1 (visit V1), day 43 (visit 2) and day 85 (visit 3)
Secondary Change in the Supraclavicular skin temperature Supraclavicular skin temperature will be measured with the FLIR T530 thermal imaging camera Change from Baseline Supraclavicular skin temperature at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Change in postmenopausal symptoms Postmenopausal symptoms will be evaluated through the Menopause Rating Scale (MRS) questionnaire. The MRS comprises 11 items representing various symptoms or complaints. Each symptom can be rated from 0 (indicating no complaints) to 4 points (indicating severe symptoms), depending on the perceived severity reported by the women completing the scale. The total MRS score ranges from 0 (asymptomatic) to 44 (maximum complaint severity). Change from Baseline postmenopausal symptoms at 6 and 12 weeks for each of the two treatments (multi-ingredient and placebo)
Secondary Adverse events Possible adverse events derived from taking study's products will be recorded in the case report form At 6 weeks (V2) and at 12 weeks (V3) for each of the two treatments (multi-ingredient and placebo)
See also
  Status Clinical Trial Phase
Completed NCT02235051 - Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors N/A
Completed NCT01635413 - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial) N/A
Completed NCT00701337 - Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route Phase 4
Recruiting NCT04705623 - Influence of Iyengar Yoga on the Bio-functional Age of Postmenopausal Women N/A
Withdrawn NCT03238703 - Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Phase 4
Completed NCT03756272 - Stellate Ganglion Block to Reduce Hot Flushes N/A
Recruiting NCT03953157 - Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors N/A
Completed NCT00338728 - Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer Phase 2
Completed NCT01482702 - Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors N/A
Not yet recruiting NCT05009238 - Effect of l S Exercises on Balance and Spatiotemporal Gait Parameters in P M Women N/A
Terminated NCT01842217 - Validation of [18F]FES for Imaging of Brain Estrogen Receptors N/A
Completed NCT01172574 - Motor Control Exercise in Osteoporotic Women N/A
Completed NCT00530582 - Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women Phase 4
Completed NCT01825785 - A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) Phase 1
Completed NCT04364061 - Post Exercise Substrate Oxidation, Appetite and Energy Intakes in Overweight/Obese Postmenopausal Women (EScAPE) N/A
Completed NCT03180294 - Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Phase 2
Recruiting NCT06445842 - Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women N/A
Completed NCT01753908 - Broccoli Sprout Extract in Treating Patients With Breast Cancer Early Phase 1
Recruiting NCT06228768 - Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer N/A
Terminated NCT01294397 - Effects of Denosumab on the Pharmacokinetics of Etanercept Phase 1